Stryker Corp. Files 2023 Annual Report on Form 10-K

Ticker: SYK · Form: 10-K · Filed: 2024-02-14T00:00:00.000Z

Sentiment: neutral

Topics: 10-K, Annual Report, Financials, Stryker, Medical Devices

TL;DR

<b>Stryker Corporation filed its 2023 Form 10-K, detailing financial performance and operations for the fiscal year ending December 31, 2023.</b>

AI Summary

STRYKER CORP (SYK) filed a Annual Report (10-K) with the SEC on February 14, 2024. Stryker Corporation filed its 2023 Form 10-K on February 14, 2024, reporting on the fiscal year ending December 31, 2023. The filing covers the company's financial performance and business operations for the fiscal year 2023. Key financial statement components like Common Stock, Additional Paid-In Capital, Retained Earnings, and Accumulated Other Comprehensive Income are detailed for multiple fiscal years. Specific debt instruments, including Senior Unsecured Notes with various maturity dates and interest rates, are listed. The report includes details on assets such as Buildings and Building Improvements, and Machinery and Equipment.

Why It Matters

For investors and stakeholders tracking STRYKER CORP, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Stryker's financial health, including its equity structure and debt obligations, which are crucial for investors assessing financial stability and investment risk. The detailed breakdown of assets and liabilities offers insights into the company's operational capacity and resource management, important for understanding its business model and future growth potential.

Risk Assessment

Risk Level: medium — STRYKER CORP shows moderate risk based on this filing. The filing is a standard annual report (10-K), which inherently contains a broad range of financial and operational information, but lacks specific forward-looking guidance or immediate material events that would elevate the risk level beyond medium.

Analyst Insight

Investors should review the detailed financial statements and risk factors within the 10-K to understand Stryker's performance and potential challenges.

Key Numbers

Key Players & Entities

FAQ

When did STRYKER CORP file this 10-K?

STRYKER CORP filed this Annual Report (10-K) with the SEC on February 14, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by STRYKER CORP (SYK).

Where can I read the original 10-K filing from STRYKER CORP?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by STRYKER CORP.

What are the key takeaways from STRYKER CORP's 10-K?

STRYKER CORP filed this 10-K on February 14, 2024. Key takeaways: Stryker Corporation filed its 2023 Form 10-K on February 14, 2024, reporting on the fiscal year ending December 31, 2023.. The filing covers the company's financial performance and business operations for the fiscal year 2023.. Key financial statement components like Common Stock, Additional Paid-In Capital, Retained Earnings, and Accumulated Other Comprehensive Income are detailed for multiple fiscal years..

Is STRYKER CORP a risky investment based on this filing?

Based on this 10-K, STRYKER CORP presents a moderate-risk profile. The filing is a standard annual report (10-K), which inherently contains a broad range of financial and operational information, but lacks specific forward-looking guidance or immediate material events that would elevate the risk level beyond medium.

What should investors do after reading STRYKER CORP's 10-K?

Investors should review the detailed financial statements and risk factors within the 10-K to understand Stryker's performance and potential challenges. The overall sentiment from this filing is neutral.

Key Dates

Glossary

10-K
An annual report required by the U.S. Securities and Exchange Commission (SEC), which gives a comprehensive summary of a company's financial performance. (This filing provides the official annual financial and operational overview for Stryker Corporation.)
Common Stock
A security that represents ownership in a corporation and a claim on part of the corporation's assets and earnings. (Key component of Stryker's equity structure, indicating shareholder investment.)
Retained Earnings
The cumulative amount of net income of a corporation that has not been distributed to its shareholders as dividends. (Reflects the company's historical profitability and its ability to reinvest earnings back into the business.)

Filing Stats: 4,428 words · 18 min read · ~15 pages · Grade level 14.1 · Accepted 2024-02-14 10:55:50

Key Financial Figures

Filing Documents

Business 1

Item 1. Business 1

Risk Factors 4

Item 1A. Risk Factors 4

Unresolved Staff Comments 10

Item 1B. Unresolved Staff Comments 10

Cybersecurity 10

Item 1C. Cybersecurity 10

Properties 11

Item 2. Properties 11

Legal Proceedings 11

Item 3. Legal Proceedings 11

Mine Safety Disclosures 11

Item 4. Mine Safety Disclosures 11 PART II Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 11

Selected Financial Data 12

Item 6. Selected Financial Data 12

Management's Discussion and Analysis of Financial Condition and Results of Operations 13

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 13

Quantitative and Qualitative Disclosures About Market Risk 21

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 21

Financial Statements and Supplementary Data 23

Item 8. Financial Statements and Supplementary Data 23 Report of Independent Registered Public Accounting Firm (PCAOB ID: 42 ) 23 Consolidated Statements of Earnings 24 Consolidated Statements of Comprehensive Income 24 Consolidated Balance Sheets 25 Consolidated Statements of Shareholders' Equity 26 Consolidated Statements of Cash Flows 27

Notes to Consolidated Financial Statements 28

Notes to Consolidated Financial Statements 28

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 41

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 41

Controls and Procedures 41

Item 9A. Controls and Procedures 41

Other Information 42

Item 9B. Other Information 42

Disclosure Regarding Foreign Jurisdictions That Prevent Inspections 42

Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections 42 PART III

Directors, Executive Officers and Corporate Governance 42

Item 10. Directors, Executive Officers and Corporate Governance 42

Executive Compensation 42

Item 11. Executive Compensation 42

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 42

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 42

Certain Relationships and Related Transactions, and Director Independence 42

Item 13. Certain Relationships and Related Transactions, and Director Independence 42

Principal Accountant Fees and Services 42

Item 14. Principal Accountant Fees and Services 42 PART IV

Exhibits, Financial Statement Schedules 43

Item 15. Exhibits, Financial Statement Schedules 43

Form 10-K Summary 46

Item 16. Form 10-K Summary 46 STRYKER CORPORATION 2023 FORM 10-K PART I

BUSINESS

ITEM 1. BUSINESS. Stryker Corporation (Stryker or the Company) is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. Our core values guide our behaviors and actions and are fundamental to how we execute our mission. Stryker was incorporated in Michigan in 1946 as the successor company to a business founded in 1941 by Dr. Homer H. Stryker, a prominent orthopaedic surgeon and inventor of several medical products. Our products are sold in approximately 75 countries through company-owned subsidiaries and branches as well as third-party dealers and distributors, and include surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; clinical communication and workflow solutions; neurosurgical and neurovascular devices; implants used in joint replacement and trauma surgeries; Mako Robotic-Arm Assisted technology; spinal devices; as well as other products used in a variety of medical specialties. Most of our products are marketed directly to doctors, hospitals and other healthcare facilities. As used herein, and except where the context otherwise requires, "Stryker," "we," "us," and "our" refer to Stryker Corporation and its consolidated subsidiaries. Business Segments and Geographic Information We segregate our operations into two reportable business segments: (i) MedSurg and Neurotechnology and (ii) Orthopaedics and Spine. Financial information regarding our reportable business segments and certain geographic information is included under "Consolidated Results of Operations" in Item 7 of this report and Note 14 to our Consolidated Financial Statements.

RISK FACTORS

ITEM 1A. RISK FACTORS. This report contains statements that are not historical facts and are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current projections about operations, industry conditions, financial condition and liquidity. Words that identify forward-looking statements include, without limitation, words such as "may," "could," "will," "should," "possible," "plan," "predict," "forecast," "potential," "anticipate," "estimate," "expect," "project," "intend," "believe," "may impact," "on track," "goal," "strategy" and words and terms of similar substance used in connection with any discussion of future operating or financial performance, an acquisition or our businesses. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Those statements are not guarantees and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results could differ materially and adversely from these forward-looking statements, historical experience or our present expectations. Some important factors that could cause our actual results to differ from our expectations in any forward-looking statements include: weakening of economic conditions, or the anticipation thereof, that could adversely affect the level of demand for our products; geopolitical risks, including from international conflicts and upcoming elections in the United States and other countries, which could, among other things, lead to increased market volatility; pricing pressures generally

View on Read The Filing